OncoMatch/Clinical Trials/NCT06500208
Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
Is NCT06500208 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide for breast cancer.
Treatment: Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide — Investigators plan to conduct a single-arm clinical study of adebelimab, a novel PD-L1 inhibitor, in the neoadjuvant treatment of early or locally advanced high-risk ER+/HER2- breast cancer, to explore whether the addition of immune checkpoint inhibitors to traditional neoadjuvant chemotherapy can improve the pathologic complete response rate (pCR) of patients, evaluate its therapeutic safety, and further analyze the biomarkers of the efficacy of neoadjuvant immunotherapy for ER+/HER2- breast cancer, so as to support the clinical application of the drug.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 IHC ER expression ≥1% (≥1%)
IHC ER expression ≥1%
Required: HER2 (ERBB2) IHC HER2 0 or 1+ (0 or 1+)
IHC HER2 0 or 1+
Required: HER2 (ERBB2) IHC HER2 2+ and no amplification in FISH test (2+ (IHC) and FISH negative)
IHC HER2 2+ and no amplification in FISH test
Required: PD-L1 (CD274) testing required
Available core needle biopsy samples for PD-L1 status testing
Allowed: PR (PGR) PR-
Grade 2 with PR- or Ki67 > 20%
Allowed: MKI67 Ki67 > 20%
Grade 2 with PR- or Ki67 > 20%
Disease stage
Required: Stage CT1C-T2N1-3, CT3-4N0-3 (clinical TNM)
Excluded: Stage IV
Grade: Grade 3Grade 2 with PR- or Ki67 > 20%
cT1c-T2N1-3 or cT3-4N0-3; Tumor Grade 3 or Grade 2 with PR- or Ki67 > 20%
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immunotherapy targeting PD-1/PD-L1/T cell receptors
History of application of any immunotherapy targeting PD-1/PD-L1/T cell receptors
Lab requirements
Blood counts
intact hematologic function
Kidney function
intact renal function
Liver function
intact liver function
Cardiac function
intact heart function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify